Bachem Group News Today

Bachem announced today that the company is reorganizing responsibilities in the Corporate Executive Committee in order to focus more on the expansion of manufacturing...

Framework agreement signed with a total committed order volume of more than CHF 500 million for the period of 2027-2031 following a joint development project. ... | March 3, 2023

/PRNewswire/ -- The "Global Merchant API Market: Analysis By Molecular Type, By Segment, By Type, By Type of Synthesis, By End-User, By Region Size And Trends...

/PRNewswire/ -- The "Global Merchant API Market: Analysis By Molecular Type, By Segment, By Type, By Type of Synthesis, By End-User, By Region Size And Trends...

Dublin, Jan. 06, 2023 (GLOBE NEWSWIRE) -- The "Global Merchant API Market: Analysis By Molecular Type, By Segment, By Type, By Type of Synthesis, By...

By Aidan Gregory 10.00 AM The IPO of PolyPeptide, the Swiss pharmaceutical ingredients company, was covered on the first morning of bookbuilding on Wednesday, according to sources close to the deal. PolyPeptide has set the price range at Sfr57 to Sfr68, implying an initial market capitalisation of Sfr1.91bn to Sfr2.24bn (€1.73bn to €2bn) – in line with expectations during pre-deal investor education. That valuation places PolyPeptide at a discount to Bachem Group and a slight premium to L...